SBFC Farmácia Clínica common mistakes
SBFC Farmácia Clínica · Understand the traps and how to avoid them.
Choosing the answer that names the drug class or mechanism that treats the disease, rather than the specific agent and regimen indicated for this patient's severity, organ function, and comorbidities (for example, picking a standard first-line antihypertensive for a patient whose renal function or pregnancy status changes the choice).
Candidates memorize disease-to-drug mappings during study and pattern-match on the diagnosis, skipping the patient-specific modifiers embedded in the stem. Under time pressure, the familiar class name feels safer than the less common but correct agent.
What to do instead
Before answering any cardiovascular or metabolic item, write down the three patient-specific modifiers present in the stem (severity, kidney or liver function, comorbidity or pregnancy, current medications) and eliminate any option that ignores even one. Practice by re-reading each stem and underlining those modifiers before looking at the options.
Treating every positive culture or fever as an indication to start or broaden antibiotics, and selecting the broadest-spectrum option as the 'safest' answer instead of de-escalating, narrowing, or stopping therapy when cultures and clinical stability allow.
Training and habit reward 'covering everything', and the fear of missing a pathogen feels safer than the risk of stewardship failure. Candidates also conflate empirical therapy decisions with definitive therapy after susceptibilities return.
What to do instead
For each antimicrobial item, explicitly state the phase (empirical, targeted, or de-escalation) and the culture data available at that phase. Choose the narrowest agent that covers the confirmed or most likely pathogen, and treat 'continue broad-spectrum despite negative cultures and clinical improvement' as a wrong answer by default.
Calculating vancomycin or aminoglycoside doses and monitoring intervals from total body weight and a standard nomogram without adjusting for renal function, obesity, or the timing of the level relative to the dose, and then interpreting a trough or peak as if it were drawn at the correct time.
Candidates memorize formulas and target ranges but skip the assumptions behind them. They also forget that a level drawn at the wrong time is uninterpretable, so they apply the target range to a mis-timed value.
What to do instead
For every TDM item, first confirm the sampling time and steady-state status, then compute clearance-based dosing (for example Cockcroft-Gault for renal function), and only then compare to the target. If the timing is wrong, the correct answer is usually to redraw rather than to adjust the dose.
Selecting a psychotropic or antiepileptic based only on the primary diagnosis while ignoring the interaction and adverse-effect profile that the stem has deliberately planted (for example, adding a drug that inhibits or induces the metabolism of an existing therapy, or one that worsens a comorbidity such as QT prolongation or weight gain).
Candidates study psychiatric and neurologic pharmacotherapy by indication and learn side-effect lists separately, so they fail to connect the two when the stem combines them. The interaction is often buried in the medication list rather than stated as the question.
What to do instead
Before choosing, list every current medication and every comorbidity in the stem, then check the candidate options against both. Flag any option that shares a metabolic pathway with an existing drug or that worsens a listed comorbidity, and prefer the option with the cleanest profile for this patient.
Missing that a respiratory, gastrointestinal, or renal scenario is really about dose adjustment or contraindication in organ impairment, and answering as if the patient had normal renal and hepatic function.
The organ-impairment clue is often a single laboratory value or a phrase such as 'stable chronic kidney disease', and candidates focus on the presenting complaint instead of the pharmacokinetic consequence.
What to do instead
Make it a habit to scan every stem for creatinine, eGFR, liver enzymes, and fluid status before reading the options. When present, decide first whether the drug needs dose reduction, avoidance, or monitoring, and eliminate options that ignore that requirement.
Applying a pharmacogenomic result as an absolute yes-or-no prescribing rule instead of translating the phenotype into expected enzyme activity and then into a concrete dose or drug-selection change, including whether the guideline recommends an alternative agent or only increased monitoring.
Candidates memorize genotype labels and a few classic pairs but not the step from phenotype to clinical action, so they either overreact (contraindicate everything) or underreact (ignore the result).
What to do instead
For each pharmacogenomics item, state the phenotype explicitly (poor, intermediate, normal, or ultrarapid metabolizer), predict whether the prodrug or active drug will accumulate or fail, and then select the action the guideline supports: avoid, reduce dose, increase dose, or monitor. Reject answers that stop at naming the genotype.
Treating a suspected adverse drug reaction as a new disease and adding a drug to treat it, rather than recognizing the temporal relationship, stopping the suspect agent, and reporting it through the appropriate notification system.
Candidates are trained to diagnose and treat, so the reflex is to manage the new symptom. Pharmacovigilance concepts such as causality assessment and mandatory notification are studied as isolated facts and not applied to clinical vignettes.
What to do instead
For any new symptom after a recent drug start or dose change, run a quick causality check (timing, known reaction pattern, improvement on withdrawal, alternative causes) before considering treatment of the symptom. If the reaction is serious or unexpected, include notification in the answer and prefer options that withdraw the suspect drug.
Answering legal and ethical items from general intuition about good practice rather than from the specific Brazilian rule that governs the situation, such as which profession may prescribe or dispense a given category, record-retention requirements, or the correct channel for a professional or ethical breach.
Candidates study law late and superficially, and everyday clinical instinct often conflicts with the formal rule. The options are usually all plausible-sounding, so intuition selects a defensible but legally wrong answer.
What to do instead
Build a one-page reference of the specific rules tested (prescription and dispensing authority, controlled-substance requirements, documentation and retention, reporting channels) and, for each legal item, identify which rule the stem is testing before evaluating options. Prefer the option that cites the formal obligation over the one that sounds clinically sensible.
Managing oncology and immunosuppression scenarios by focusing only on the antineoplastic or immunosuppressive regimen while neglecting supportive care, prophylaxis, and the interaction between the regimen and the patient's other drugs, counts, or organ function.
The oncology and transplant content is dense, so candidates memorize regimens and skip the supportive-care and monitoring framework that most questions actually test. They also forget that immunosuppressants have narrow therapeutic indices and major interactions.
What to do instead
For each oncology or transplant item, systematically check four things: regimen and indication, required prophylaxis (antiemetic, antimicrobial, growth factor, or graft-versus-host measures as applicable), monitoring parameters, and interactions with the current medication list. Answer only after all four have been considered.
Choosing an answer that reflects what the candidate would do in their own practice setting rather than the pharmaceutical care process the item is testing, skipping steps such as identifying and resolving drug therapy problems, documenting the intervention, and defining a follow-up and monitoring plan.
Candidates with practice experience default to habitual workflow and do not map the vignette onto the formal care-process sequence, so they pick a clinically reasonable action that omits the documentation or follow-up step the question rewards.
What to do instead
For pharmaceutical care items, walk the sequence explicitly: assess the problem, identify the drug therapy problem, propose the intervention, document it, and set the monitoring and follow-up. Choose the option that completes the sequence rather than the one that only takes the immediate clinical action.